

Supplemental Approvals

Generic Name (Trade Name—Company)

July 31, 2018

Enzalutamide

(*Xtandi*—Astellas, Pfizer)

Agent has new indication for treatment of nonmetastatic castration-resistant prostate cancer

Uses/Notes

Astellas Pharma and Pfizer announced FDA approval of enzalutamide for treatment of men with nonmetastatic castration-resistant prostate cancer (CRPC). It is the first and only oral medication FDA approved for both nonmetastatic and metastatic CRPC.

Enzalutamide was first approved by FDA in 2012 to treat patients with metastatic CRPC who had previously received docetaxel, and in 2014, it was granted approval for chemotherapy-naïve men with metastatic CRPC.

The updated label is based on results from the Phase III PROSPER trial, which demonstrated that use of enzalutamide plus androgen deprivation therapy (ADT) significantly reduced the risk of developing metastasis or death compared with ADT alone in men with nonmetastatic CRPC.

The most common adverse reactions in the clinical trial were asthenic conditions, hot flush, hypertension, dizziness, nausea, and fall.

Source URL:

<http://aphanet.org/supplemental-approvals/agent-has-new-indication-treatment-nonmetastatic-castration-resistant>

A_{PhA} DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in A_{PhA} DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of A_{PhA}. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in A_{PhA} DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.